Inscrição na biblioteca: Guest
Critical Reviews™ in Oncogenesis

Publicou 4 edições por ano

ISSN Imprimir: 0893-9675

ISSN On-line: 2162-6448

SJR: 0.395 SNIP: 0.322 CiteScore™:: 2.5 H-Index: 54

Indexed in

Precise Diagnosis and Treatment of Thymic Epithelial Tumors Based on Molecular Biomarkers

Volume 22, Edição 5-6, 2017, pp. 507-514
DOI: 10.1615/CritRevOncog.2017020577
Get accessGet access

RESUMO

Thymic epithelial tumors (TETs), including thymoma and thymic carcinoma, are rare malignant tumors. The mainstay of treatment patients with TET is surgical resection, and chemotherapy is necessary for patients with tumor invasion or metastasis who are unable to undergo complete radical excision. However, for those patients who are resistant to chemotherapy, targeted therapy has become the most popular tumor treatment program, as well as for thymic tumors. Many genes implicated in tumorigenesis and metastasis have also been reported to be therapeutic targets in thymic malignancies. A significant advance in TET treatment may derive from the identification of novel molecular biomarkers that can improve the diagnosis, prognosis, and treatment of tumors. We review a number of case reports and small clinical trials reporting that a few inhibitors, such as sorafenib and sunitinib, are effective in the treatment of thymoma. In this review, we describe the current potential drug targets and their roles in the development of thymic malignancy.

CITADO POR
  1. Feng Feiling, Wu Xiaobing, Shi Xiaoliang, Gao Qingxiang, Wu Yue, Yu Yong, Cheng Qingbao, Li Bin, Yi Bin, Liu Chen, Hao Qing, Zhang Lin, Gao Chunfang, Jiang Xiaoqing, Comprehensive analysis of genomic alterations of Chinese hilar cholangiocarcinoma patients, International Journal of Clinical Oncology, 26, 4, 2021. Crossref

Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa Políticas de preços e assinaturas Begell House Contato Language English 中文 Русский Português German French Spain